Generics Dr Reddy's Laboratories (NYSE: RDY), India's second largest drugmaker, has announced its audited consolidated financial results for the fourth quarter and full year ended March 31, 2013, showing that consolidated revenues for the year were 116.3 billion rupees ($2.13 billion), recording year-on-year growth of 20%. Excluding the beneficial impact of olanzapine (Eli Lilly's antipsychotic drug Zyprexa) exclusivity in fiscal 2012, sales registered year-on-year growth of 26%. 14 May 2013